Jens T.
- Country
- Austria
- Department
- 3701; Main
Research Overview
- Efficacy and Safety of Sarilumab Dose Levels with a 52‑Week Prednisone Taper in Adults with Early Polymyalgia Rheumatica: Randomized Double‑Blind Placebo‑Controlled Trial
- A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis
- Evaluation of Anifrolumab Efficacy and Safety in Systemic Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 119 of 258 partner sites.
Specializations
Autoimmune Rheumatic Diseases
Specializes in investigating novel treatments for systemic sclerosis, with particular focus on both diffuse cutaneous forms and lung involvement. The investigator studies interventions aimed at improving lung function and managing disease progression in dcSSc.
- Systemic sclerosis therapeutic approaches
- Lung function assessment
- Cutaneous manifestations
Vasculitis and Inflammatory Disorders
Conducts research in various forms of vasculitis, including ANCA-associated vasculitis, giant cell arteritis, and eosinophilic granulomatosis with polyangiitis. The investigator evaluates novel therapeutic approaches for these conditions.
- ANCA vasculitis treatment
- Giant cell arteritis management
- EGPA therapeutic interventions
Complex Autoimmune Conditions
Focuses on advanced therapeutic approaches for systemic lupus erythematosus with renal involvement and idiopathic inflammatory myopathies. The investigator explores innovative treatments for these challenging autoimmune conditions.
- Lupus nephritis management
- Inflammatory myopathies
- Dermatomyositis treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.